Suleyman Eralp al Bellibas
Advisory Board Member @Iq Consortium
Signup · Get unlimited contacts
WORK HISTORY
Advisory Board Member @Iq Consortium
DC, US
Novartis representative for Clinical Pharmacology Leadership Group in IQ Consortium
EDUCATION
Ege University
PhD Eq., Medical Pharmacology
Università degli Studi di Milano
Fellow, Medical Pharmacology
NATO ASI Erice International School of Pharmacology
New Trends in Pharmacokinetics; Pharmacovigilance
University of California, San Francisco
MSD International fellow, Postdoc, Clinical Pharmacology
Ankara University
Doctor of Medicine (M.D.), Medicine
SKILLS
ABOUT SULEYMAN ERALP AL BELLIBAS
Physician-Scientist/Pharmaceutical/Biotech R&D Executive/Translational Medicine/Clinical Pharmacology Subject Matter Expert/Drug Developer with an exceptional track record in Early Development for Adult and Pediatric Indications-20+ years of innovation experience in the US and Global pharmaceutical/biotech industry (Roche, Johnson & Johnson, Novartis, The Medicines Company, Former VP at Parexel)- Postdoc training at UCSF as MSD International Fellow in Clinical Pharmacology- Fellow of the American Heart Association- Scientific Advisor for INDdose, a smartphone app to calculate estimated maximum safe starting dose in First in Human clinical trials- Early Phase Drug Development/Translational Medicine/Clinical Pharmacology Expertise for Small Molecules and Biologics- Contributed development activities of 100+ NMEs at various phases of development ranging from IND/Phase 1 to NDA and Global Registration trials- Co-developer 6 successfully filed and approved first in class NDAs- Fuzeon®: First in class HIV fusion inhibitor drug. Approved for Adult and Pediatric indications in less than two years of clinical development time-Exelon Patch®: First transdermal therapeutics for Alzheimer’s Dementia-Orbactiv®: First single-dose antibiotic for Skin and Skin structure infections-Kengreal®: First and only intravenous P2Y12 antiplatelet agent approved as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events-Leqvio®: First in class siRNA PCSK9 inhibitor to lower cholesterol-Fabhalta®: First in class Factor B inhibitor for several rare immunology/hematology/nephrology indications.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.